Seizert Capital Partners LLC bought a new stake in shares of Chemed Co. (NYSE:CHE) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 18,199 shares of the company’s stock, valued at approximately $3,325,000. Seizert Capital Partners LLC owned 0.11% of Chemed as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the stock. Glen Harbor Capital Management LLC increased its position in Chemed by 11.4% in the first quarter. Glen Harbor Capital Management LLC now owns 624 shares of the company’s stock valued at $114,000 after buying an additional 64 shares during the last quarter. TrimTabs Asset Management LLC increased its position in Chemed by 88.7% in the first quarter. TrimTabs Asset Management LLC now owns 732 shares of the company’s stock valued at $134,000 after buying an additional 344 shares during the last quarter. Tyers Asset Management LLC purchased a new position in Chemed during the fourth quarter valued at approximately $124,000. Flinton Capital Management LLC purchased a new position in Chemed during the fourth quarter valued at approximately $157,000. Finally, Whittier Trust Co. increased its position in Chemed by 4.6% in the first quarter. Whittier Trust Co. now owns 1,177 shares of the company’s stock valued at $215,000 after buying an additional 52 shares during the last quarter. 99.72% of the stock is currently owned by institutional investors.
Shares of Chemed Co. (NYSE:CHE) traded up 0.21% during midday trading on Friday, reaching $197.73. The company had a trading volume of 92,797 shares. Chemed Co. has a one year low of $126.54 and a one year high of $216.01. The company has a 50 day moving average price of $193.43 and a 200-day moving average price of $171.80. The firm has a market capitalization of $3.18 billion, a P/E ratio of 29.01 and a beta of 1.21.
Chemed (NYSE:CHE) last released its quarterly earnings results on Wednesday, April 26th. The company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.78 by $0.04. The firm had revenue of $405.90 million during the quarter, compared to analyst estimates of $399.75 million. Chemed had a net margin of 6.77% and a return on equity of 23.95%. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.62 EPS. On average, analysts anticipate that Chemed Co. will post $7.95 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 14th. Stockholders of record on Thursday, May 25th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Tuesday, May 23rd. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.53%. Chemed’s dividend payout ratio (DPR) is currently 16.59%.
Separately, Zacks Investment Research downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd.
In other news, Director Donald E. Saunders sold 400 shares of the business’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $204.85, for a total transaction of $81,940.00. Following the completion of the transaction, the director now directly owns 9,886 shares in the company, valued at approximately $2,025,147.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction on Tuesday, May 2nd. The shares were sold at an average price of $205.11, for a total transaction of $820,440.00. Following the transaction, the insider now owns 148,943 shares of the company’s stock, valued at $30,549,698.73. The disclosure for this sale can be found here. Insiders have sold a total of 30,544 shares of company stock valued at $5,621,612 over the last 90 days. Company insiders own 5.32% of the company’s stock.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Co. and related companies with MarketBeat.com's FREE daily email newsletter.